第二项头对头PD-1 III 期试验成功,第四项中国内地肺癌III 期研究即将启动:公司宣布,依沃西单抗联合化疗对比替雷利珠单抗+化疗一线治疗鳞状非小细胞肺癌(1L NSCLC)的中国内地临床试验(AK112-306/HAMONi-6研究)已取得强阳性结果,时间早于市场此前预期。试验达到PFS 的主要终点,统计学(HR 值)和临床(PFS 延长绝对值)角度均有显著获益;依沃西组在PD-L1 阳性及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.